Pulmonary arterial hypertension (PAH), a subtype of pulmonary hypertension (PH), is a chronic, life-threatening disease that is characterized by increased resistance in the pulmonary circulation caused by progressive pulmonary artery remodeling and constriction of the pulmonary vasculature (Buckley et al 2013, Wu et al 2013). PH is defined as a mean pulmonary arterial pressure (mPAP) of ≥ 20 mmHg at rest. In the past, PH was hemodynamically defined by an mPAP ≥ 25 mmHg; however, this cutoff was somewhat arbitrary and targeted at avoiding the over-detection of PH (Rubin et al 2019).

Additionally, for patients with PAH, the diagnosis requires a pulmonary vascular resistance (PVR) ≥ 3 Wood units (Rubin et al 2019). PAH often manifests with clinical symptoms such as shortness of breath and decreased functional capacity, and eventually leads to right heart failure and death (Gomberg-Maitland et al 2011).

Early recognition of PAH is essential and the gold standard for the clinical diagnosis of PAH is right heart catheterization (Buckley et al 2013).

According to the 6th World Symposium on PH, the condition is classified into 5 World Health Organization (WHO) groups (Simonneau et al 2019):
- Group 1 – PAH
- Group 2 – PH secondary to left heart disease
- Group 3 – PH secondary to lung diseases and/or hypoxia
- Group 4 – PH due to pulmonary artery obstructions
- Group 5 – PH with unclear and/or multifactorial mechanisms

Group I encompasses PAH, including idiopathic PAH, heritable PAH, drug- and toxin-induced PAH, and PAH associated with other disorders such as connective tissue disease, portal hypertension, human immunodeficiency virus infection, congenital heart disease, and schistosomiasis (Simonneau et al 2019).

In addition to the diagnostic classification, patients may be stratified according to their WHO functional capacity, which was adapted from the New York Heart Association (NYHA) classification of left heart failure. A brief description of these functional classes (FC) is as follows (Stringham et al 2010):
- Class I: No limitation of physical activity
- Class II: Slight limitation of physical activity
- Class III: Marked limitation of physical activity
- Class IV: Inability to carry out any physical activity without symptoms

The prevalence of WHO Group 1 PAH has been estimated at 7 to 26 cases per million adults (Pogue et al 2016). The disease has a poor prognosis and an approximate mortality rate of 15% within 1 year on therapy (McLaughlin et al 2009). The median survival in the 1980s was 2.8 years; this had improved to 7 years in the late 2000s (Pogue et al 2016).

Pulmonary artery obstruction (Group 4), including chronic thromboembolic PH (CTEPH), is a leading cause of severe PH that results from thrombus formation leading to fibrous stenosis or complete obliteration of pulmonary arteries.
- The incidence of CTEPH is uncertain, but in a 2017 meta-analysis, the overall pooled incidence after pulmonary embolism was 2.3% (Ende-Verhaar et al 2017).

Specific agents to treat PAH primarily target 3 pathways critical to its pathobiology: the prostacyclin, endothelin, and nitric oxide pathways (Wu et al 2013). There are currently 10 molecular entities within 5 therapeutic classes that are Food and Drug Administration (FDA)-approved for the treatment of PAH (Lexicomp 2020).
- Drugs active within the prostacyclin pathway are the prostacyclin analogues (PCAs) or prostanooids (intravenous [IV] epoprostenol; inhaled iloprost; and IV, subcutaneous [SC], inhaled, and oral treprostinil) and a prostacyclin receptor agonist (oral selexipag).
- Drugs active within the endothelin pathway are the endothelin receptor antagonists (ERAs) (oral ambrisentan, oral bosentan, and oral macitentan).
- Drugs active within the nitric oxide pathway are the phosphodiesterase-type-5 (PDE-5) inhibitors (IV and oral sildenafil and oral tadalafil) and a soluble guanylate cyclase (sGC) stimulator (oral riociguat).
• The goals of treatment include improvement in the patient’s symptoms, quality of life (QOL), and survival. The optimal therapy for a patient should be individualized, taking into account many factors including severity of illness, route of administration, side effects, comorbid illness, treatment goals, and clinician preference (McLaughlin et al 2009).
• Initial management of PAH includes the use of warfarin, diuretics, and/or oxygen depending on the patient’s diagnosis and symptoms. Prior to the initiation of advanced therapy, patients with PAH should undergo a vasoreactivity test. Oral calcium channel blockers (CCBs) are indicated only for patients who have a positive acute vasodilator response to testing (Galiè et al 2015[b], Klinger et al 2019, McLaughlin et al 2009).
• For patients who do not have a positive acute vasodilator response to testing and are considered at risk (NYHA Class II or III) based on clinical assessment, combination therapy with certain agents is preferred initially but monotherapy can be considered if combination therapy is not an option. Agents that can be used include ERAs, PDE-5 inhibitors, an sGC stimulator, and a prostacyclin receptor (IP) agonist. In patients with high-risk disease, continuous treatment with an IV PCA therapy (epoprostenol or treprostinil) would be recommended. Add-on therapy may be considered if patients do not respond adequately to initial therapy (Barst, 2009, Galiè et al 2015[b], Klinger et al 2019, McLaughlin et al 2009).
• The PAH agents are FDA-approved for the treatment of patients with WHO Group I PAH; however, there are differences in the study populations for which their FDA-approvals were based (McLaughlin et al 2009).
• Adempas (riociguat) is a first-in-class sGC stimulator with a dual mode of action involving endogenous nitric oxide that leads to increased generation of cyclic guanosine monophosphate (cGMP) with subsequent vasodilation. This agent is also FDA-approved for treating adults with persistent/recurrent CTEPH after surgical treatment or inoperable CTEPH. Adempas is the first and only drug to be FDA-approved in the treatment of CTEPH. Pulmonary endarterectomy is curative for CTEPH, but it is technically demanding which may limit access to its use as a treatment (Archer 2013).
• In PAH, prostacyclin synthase is reduced, resulting in inadequate production of prostacyclin I2, a potent vasodilator with antiproliferative effects and an inhibitor of platelet aggregation (McLaughlin et al 2009). The PCAs, iloprost and treprostinil, were developed as chemically stable alternatives to epoprostenol, which requires continuous IV infusion due to its lack of stability (Asaki et al 2015). Orenitram (treprostinil) is the first FDA-approved oral PCA. It may represent a more convenient dosage form than the other treprostinil formulations (Remodulin and Tyvaso). However, patients with more severe PAH are likely to receive infused PCA rather than oral therapy (McLaughlin et al 2009). Among these agents, epoprostenol IV is the only agent that has demonstrated improved patient survival in high-risk PAH patients (Galiè et al 2015[b]). Uptravi (selexipag) works at the same pathway as the PCAs, but activates the IP receptor, also known as the prostacyclin receptor. Orenitram and Uptravi are the only orally administered agents that work within the prostacyclin pathway (Asaki et al 2015).
• Endothelial dysfunction in PAH causes increased production of endothelin-1 resulting in vasoconstriction, which is mediated by the endothelin receptors, ETα and ETβ. Stimulation of ETα causes vasoconstriction and cell proliferation, while stimulation of ETβ results in vasodilatation, antiproliferation and endothelin-1 clearance. The ERAs (Letairis [ambrisentan], Opsumit [macitentan], and Tracleer [bosentan]) competitively bind to both receptors with different affinities. Letairis and Opsumit are highly selective for the ETα receptor, while Tracleer is slightly selective for the ETα receptor over the ETβ receptor. In addition, Opsumit has a pharmacologically active metabolite and is considered “tissue-targeting” because it displays high affinity and sustained occupancy at the ET receptors in human pulmonary arterial smooth muscles. However, the clinical significance of receptor affinities of the ERAs has not been established (McLaughlin et al 2009). Of the ERAs, Letairis is approved to be used in conjunction with Adcirca to reduce the risks of disease progression and hospitalization for worsening PAH and to improve exercise ability (Klinger et al 2019, Letairis prescribing information 2019). In addition to treatment of PAH (WHO Group I) in adults, Tracleer is approved for use in children 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (Tracleer prescribing information 2019).
• In patients with PAH, there is also an impaired release of nitric oxide by the vascular endothelium, thereby reducing cGMP concentrations. The PDE-5 enzyme is the predominant phosphodiesterase in the pulmonary vasculature and is responsible for the degradation of cGMP. The PDE-5 inhibitors, Revatio (sildenafil) and Adcirca (tadalafil), increase the concentrations of cGMP resulting in relaxation of the pulmonary vascular bed.
• Medispan class: Cardiovascular Agents, Miscellaneous – Prostaglandin Vasodilators; Pulmonary Hypertension: Endothelin Receptor Antagonists, Phosphodiesterase Inhibitors, Prostacyclin Receptor Agonist, and Soluble Guanylate Cyclase Stimulator.
### Table 1. Medications Included Within Class Review

<table>
<thead>
<tr>
<th>Drug</th>
<th>Generic Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ERAs</strong></td>
<td></td>
</tr>
<tr>
<td>Letairis (ambrisentan)</td>
<td>✓</td>
</tr>
<tr>
<td>Opsumit (macitentan)</td>
<td>-</td>
</tr>
<tr>
<td>Tracleer (bosentan)</td>
<td>✓ *</td>
</tr>
<tr>
<td><strong>PDE-5 inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Adcirca (tadalafil)</td>
<td>✓ †</td>
</tr>
<tr>
<td>Revatio (sildenafil)</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Prostacyclin receptor agonist</strong></td>
<td></td>
</tr>
<tr>
<td>Upravi (selexipag)</td>
<td>-</td>
</tr>
<tr>
<td><strong>PCAs</strong></td>
<td></td>
</tr>
<tr>
<td>Flolan (epoprostrenol)</td>
<td>✓</td>
</tr>
<tr>
<td>Veletri (epoprostrenol)</td>
<td>-</td>
</tr>
<tr>
<td>Orenitram (treprostinil)</td>
<td>-</td>
</tr>
<tr>
<td>Remodulin (treprostinil)</td>
<td>✓</td>
</tr>
<tr>
<td>Tyvaso (treprostinil)</td>
<td>-</td>
</tr>
<tr>
<td>Ventavis (iloprost)</td>
<td>-</td>
</tr>
<tr>
<td><strong>sGC stimulator</strong></td>
<td></td>
</tr>
<tr>
<td>Adempas (riociguat)</td>
<td>-</td>
</tr>
</tbody>
</table>

*Generic available for the tablet only. A generic is not available for the tablet for oral suspension formulation.
†Alyq (branded generic) and generically-named products.

*(Drugs@FDA 2020, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2020)*

### INDICATIONS

#### Table 2. FDA-approved Indications

<table>
<thead>
<tr>
<th>Indication</th>
<th>Adcirca (tadalafil)</th>
<th>Adempas (riociguat)</th>
<th>Flolan (epoprostrenol)</th>
<th>Letairis (ambrisentan)</th>
<th>Opsumit (macitentan)</th>
<th>Orenitram (treprostinil)</th>
<th>Remodulin (treprostinil)</th>
<th>Revatio (sildenafil)</th>
<th>Tracleer (bosentan)</th>
<th>Tyvaso (treprostinil)</th>
<th>Upravi (selexipag)</th>
<th>Veletri (epoprostrenol)</th>
<th>Ventavis (iloprost)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of PAH (WHO Group I) to improve exercise ability and delay clinical worsening</td>
<td>✓ *</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) to improve exercise ability and capacity</td>
<td>✓ #</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) to delay disease progression and reduce risk of hospitalization</td>
<td>✓ **</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) to improve exercise capacity, to improve WHO FC, and to delay clinical worsening</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) to improve a composite endpoint of exercise tolerance, symptoms, and lack of deterioration</td>
<td></td>
<td></td>
<td></td>
<td>§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) to delay disease progression and improve exercise capacity</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For patients who require transition from epoprostenol, to reduce the rate of clinical deterioration; risks and benefits of each drug should be carefully considered prior to transition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of persistent/recurrent CTEPH (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO FC</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I), in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability</td>
<td>✓ *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of PAH (WHO Group I) in pediatric patients aged ≥ 3 years with idiopathic or congenital PAH to improve pulmonary vascular resistance, which is expected to improve exercise ability</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** CTEPH=chronic thromboembolic pulmonary hypertension; FC=functional class; NYHA=New York Heart Association, PAH=pulmonary arterial hypertension, WHO=World Health Organization.

*Studies establishing effectiveness included predominantly patients with WHO FC II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).

§The delay in clinical worsening was demonstrated when Revatio was added to background epoprostenol therapy. Studies establishing effectiveness were short-term (12 to 16 weeks) and included predominately patients with NYHA FC II to III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (25%).
†Studies establishing effectiveness included predominately patients with WHO FC II to IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital systemic-to-pulmonary shunts (18%).

‡Studies establishing effectiveness included predominately patients with NYHA FC II to III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

§Studies included predominately patients with NYHA FC III to IV symptoms and etiologies of idiopathic or heritable PAH (49%) or PAH associated with connective tissue diseases (51%).

¶The studies that established effectiveness included predominantly patients with WHO FC II to III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

‡Studies establishing effectiveness included predominately patients with NYHA FC II to IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), and PAH associated with connective tissue diseases (19%).

ΩStudies establishing effectiveness included predominately patients with NYHA FC III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).

ΩΩStudies establishing effectiveness included predominately patients with NYHA FC III to IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.

**Effectiveness was established in a long-term study in PAH patients with predominantly WHO FC II to III symptoms treated for an average of 2 years. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).

††Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominantly patients with WHO FC II to III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

‡‡Studies establishing effectiveness included predominately patients with NYHA FC III to IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%).

§§Effectiveness was established in a long-term study in PAH patients with WHO FC II to III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue diseases (29%), and PAH associated with congenital heart disease with repaired shunts (10%).


NOTE: Information on indications, mechanism of action, pharmacokinetics, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

**CLINICAL EFFICACY SUMMARY**

**Adcirca (tadalafil)**

- Adcirca was evaluated in the PHIRST study, a 16-week, randomized, double-blind, placebo-controlled trial consisting of 405 patients with predominantly WHO FC II or III symptoms. Treatment with Adcirca significantly improved exercise capacity, as measured by the 6MWD and reduced clinical worsening compared to placebo (Galié et al 2009). In a 52-week extension trial, PHIRST-2, the improvements in 6MWD observed at the end of PHIRST appeared to be maintained through week 52 of PHIRST-2 (68 weeks total). In addition, 34% of patients enrolled in PHIRST-2 experienced an improvement in exercise capacity, as measured by the 6MWD, compared to placebo for at least 1 year. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).

- Efficacy was shown in patients on Adcirca monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominantly patients with WHO FC II to III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).

- The studies that established effectiveness included predominantly patients with NYHA FC III to IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%).

**Adempas (riociguat)**

- The efficacy and safety of Adempas were evaluated in CHEST-1, a multinational, multicenter, double-blind, 16-week trial in 261 adult patients with CTEPH. The majority of patients were WHO FC II (31%) or class III (64%). The primary endpoint of CHEST-1 was change from baseline in 6MWD after 16 weeks. Secondary endpoints included changes in baseline true total pulmonary vascular resistance (PVR), N-terminal pro-brain natriuretic peptide (NT-proBNP) level, WHO FC, time to clinical worsening, Borg dyspnea score, QOL variables, and safety. Improvements in walking distance occurred beginning at week 2. At week 16, the placebo adjusted mean increase in 6MWD within the Adempas group was 46 m (95% confidence interval [CI], 25 m to 67 m; p < 0.001) (Ghofrani et al 2013[a]).

- An open-label, non-comparative, extension study (CHEST-2) included 237 patients who completed CHEST-1. CHEST-2 consisted of an 8-week, double-blind dose-adjustment phase, followed by an open-label study phase that continued until Adempas received official approval and became commercially available. At the March 2013 cut-off date, 211 patients (89%) were receiving ongoing treatment, and 179 (76%) had received over 1 year of treatment. The safety profile of Adempas in CHEST-2 was similar to CHEST-1, with no new safety signals. Improvements in 6MWD and WHO FC were observed in CHEST-2 persisted for up to 1 year in CHEST-2. In the observed population at 1 year, mean±standard deviation (SD) 6MWD had changed by 51±62 m (n = 202) versus CHEST-1 baseline (n = 237), and WHO FC had improved, stabilized, or worsened in 47, 50, or 3% of patients (n = 202) versus CHEST-1 baseline (n = 237). Of patients treated for 1 year in CHEST-2, 145 (92%) out of 157 were continuing to receive Adempas monotherapy, and 12 (8%) patients were receiving additional PH-specific medication (8 [5%] were receiving ERAs.
The safety and efficacy of chronically-infused Flolan were evaluated in 2 similar, open-label, randomized trials of 8 to 12 weeks’ duration comparing Flolan plus conventional therapy (eg, anticoagulants, oral vasodilators, diuretics, digoxin, oxygen) with conventional therapy alone in idiopathic or heritable PAH (NYHA Class II to IV) patients (n = 106). The average Flolan dose was 9.2 ng/kg/min at the trials’ end. A statistically significant improvement was observed in the 6MWD in patients receiving Flolan plus conventional therapy for 8 to 12 weeks compared with those receiving conventional therapy alone. Improvements were noted as early as week 1. Increases in exercise capacity were accompanied by statistically significant improvement in dyspnea and fatigue, as measured by the Chronic Heart Failure Questionnaire and the Dyspnea Fatigue Index, respectively.

**Flolan (epoprostenol)**

- The efficacy and safety of Adempas were also evaluated in PATENT-1, a multinational, multicenter, double-blind, 12-week trial in 443 adult patients with PAH as defined by PVR > 300 dyn·sec·cm⁻⁵ and a PAPmean > 25 mmHg. In this study, 50% of the patients were treatment-naïve with respect to PAH therapy, 44% were pre-treated with an ERA, and 6% were pretreated with a PCA (inhaled, oral, or SC). Patients were randomized to 1 of 3 treatment groups: placebo (n = 126), an exploratory capped titration arm of Adempas 1.5 mg 3 times daily (n = 63), or a capped maximum dose of Adempas 2.5 mg 3 times daily (n = 254). The primary endpoint of PATENT-1 was change from baseline in 6MWD after 12 weeks in the Adempas 2.5 mg group compared to placebo. Secondary endpoints included changes from baseline in PVR, NT-proBNP, WHO FC, time to clinical worsening, Borg dyspnea score, QOL variables, and safety. At week 12, the placebo-adjusted mean increase in 6MWD within the Adempas 2.5 mg treatment group was 36 m (95% CI, 20 m to 52 m, p < 0.001). The group receiving the capped dose at 1.5 mg was excluded from the efficacy analysis (Ghofrani et al 2013[b]).

- An open-label, non-comparative, extension study (PATENT-2) included 396 patients who completed PATENT-1. PATENT-2 consisted of an 8-week, double-blind dose-adjustment phase, followed by an open-label study phase that continues until all patients have transitioned to the commercially available drug. A total of 197 patients received Adempas monotherapy and 199 received Adempas in combination with an ERA or prostanoid, or both. The primary objective of the study was to assess the safety and tolerability of long-term Adempas treatment. Assessments took place at entry to PATENT-2, at weeks 2, 4, 6, 8, and 12, and every 3 months thereafter. At the March 2013 data cut-off, 324 patients (82%) were receiving ongoing treatment and 84% had received 1 year or more of treatment. Mean treatment duration was 95 weeks (median 91 weeks), and cumulative treatment exposure was 718 patient-years (Rubin et al 2015). An exploratory analysis concluded that there was a significant association between overall survival and 6MWD, NT-proBNP concentration, and WHO FC at baseline (p = 0.0006, 0.0225, and 0.0191, respectively), and at follow-up (p = 0.021, 0.0056, and 0.0048, respectively). Additionally, short-term improvements were associated with long-term survival and worsening-free survival. The estimated survival rate was 97% (95% CI, 95 to 98%) and rate of clinical worsening-free survival was 88% (95% CI, 85 to 91%) at 1 year and 79% (95% CI, 74 to 82%) at 2 years (Ghofrani et al 2016). Certain outcomes were considered exploratory, so data from this study must be interpreted cautiously.

**Flolan (epoprostenol)**

- The safety and efficacy of chronically-infused Flolan were evaluated in 2 similar, open-label, randomized trials of 8 to 12 weeks’ duration comparing Flolan plus conventional therapy with conventional therapy alone. The mean Flolan dose was 11.2 ng/kg/min at the end of week 12. Statistically significant improvement was observed in the 6MWD in patients receiving continuous Flolan plus conventional therapy for 12 weeks compared to those receiving conventional therapy alone. Increases in exercise capacity were accompanied by statistically significant improvement in dyspnea and fatigue, as measured by Borg Dyspnea Index and Dyspnea Fatigue Index. At week 12, the NYHA FC improved in 41% of patients treated with Flolan plus conventional therapy compared to none of the patients treated with conventional therapy alone. However, the majority of patients in both treatment groups showed no change in FC, with 4% of the Flolan plus conventional therapy group and 27% of conventional therapy group alone worsening.
**Letairis (ambrisentan)**

- The safety and efficacy of Letairis in the treatment of PAH were established in the ARIES trials. ARIES-1 and ARIES-2 were 12-week, randomized, double-blind, placebo-controlled trials that compared Letairis to placebo in 394 patients. Compared to placebo, treatment with Letairis resulted in a significant increase in exercise capacity as measured by 6MWD (Galiè et al 2008[a]). ARIES-E was the open-label extension study for ARIES-1 and ARIES-2. After 1 year of treatment, there was an improvement in 6MWD in the 2.5, 5 and 10 mg Letairis groups (25, 28 and 37 m, respectively). After 2 years of treatment, the improvement was sustained in the 5 and 10 mg groups (23 and 28 m), but not the 2.5 mg group (7 m) (Oudiz et al 2009).
- ARIES-3 was a long-term, open-label, single-arm, safety, and efficacy study of Letairis in patients with PH receiving Letairis 5 mg once daily for 24 weeks. The primary endpoint was change from baseline in 6MWD at week 24. Secondary efficacy endpoints included change in plasma NT-proBNP, Borg Dyspnea Index, WHO FC, time to clinical worsening of PAH, survival and adverse events (AEs). A total of 224 patients with PH due to idiopathic and familial PAH (31%), connective tissue disease (18%), chronic hypoxemia (22%), chronic thromboembolic disease (13%), or other etiologies (16%) were enrolled, and 53% of patients received stable background PAH therapies. After 24 weeks of therapy, there was an increase in 6MWD of 21 m (95% CI, 12 to 29), and a decrease in NT-proBNP of -26% (95% CI, -34 to -16%) observed in the overall population compared to baseline. However, increases in 6MWD were not observed in several non-Group 1 PH subpopulations. Peripheral edema, headache, and dyspnea were the most common AEs (Badesch et al 2012).
- The AMBITION trial (n = 610) was a double-blind, randomized, Phase 3/4 trial, which compared combination treatment with Letairis plus Adcirca to monotherapy with each in patients with WHO FC II or III symptoms. The study protocol was amended during the trial resulting in 17% of the initial protocol patients being excluded from the analysis, and treatment was administered significantly longer in the combination group vs. monotherapy groups (p = 0.03). Results demonstrated that patients receiving combination therapy had significantly fewer clinical failure events (defined as death, hospitalization for worsening PAH, disease progression, or unsatisfactory long-term clinical response) compared to patients receiving individual monotherapy (combination vs. pooled-monotherapy group, hazard ratio [HR] 0.5; 95% CI, 0.35 to 0.72; p < 0.001). Primary event outcomes were primarily driven by hospitalization. No significant differences were observed in terms of change in FC or all-cause death. The most common AEs that occurred more often with combination treatment included peripheral edema, headache, nasal congestion, anemia, and bronchitis (Galiè et al 2015[a]). Based on results from the AMBITION trial, the FDA-approved Letairis in combination with Adcirca to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability (Letairis prescribing information 2019).

**Opsumit (macitentan)**

- The efficacy and safety of Opsumit on progression of PAH were demonstrated in a multicenter, Phase 3, event-driven, placebo-controlled trial (SERAPHIN) in 742 patients with symptomatic PAH (WHO FC II, III, or IV) with or without concomitant use of oral PDE-5 inhibitors, oral or inhaled PCAs, CCBs, or L-arginine for the 3 month period prior to randomization. Patients were randomized to placebo (n = 250), Opsumit 3 mg once daily (n = 250), or Opsumit 10 mg once daily (n = 242). The mean treatment durations were 85.3, 99.5, and 103.9 weeks in the placebo, Opsumit 3 mg, and Opsumit 10 mg groups, respectively. The primary study endpoint was time to the first occurrence of death, a significant morbidity event (defined as atrial septostomy, lung transplantation, initiation of IV or SC PCAs), or other worsening of PAH (defined as a sustained ≥ 15% decrease from baseline in 6MWD, worsening of PAH symptoms as determined by worsening of WHO FC, and need for additional treatment of PAH) during the double-blind treatment plus 7 days. Pre-specified secondary endpoints included change from baseline to month 6 in the 6MWD and percentage of patients with improvement in WHO FC. Other critical pre-specified secondary endpoints were time to PAH death or PAH hospitalization. The primary endpoint occurred in 46.4%, 38%, and 31.4% of the patients in the placebo, Opsumit 3 mg, and Opsumit 10 mg groups, respectively. Opsumit 10 mg once-daily therapy resulted in a 45% reduction compared to placebo (HR, 0.55; 97.5% CI, 0.39 to 0.76; p < 0.001) in the occurrence of the primary endpoint to the end of the double-blind treatment. The beneficial effect of Opsumit 10 mg was primarily due to its reduction in clinical worsening (Pulido et al 2013).
  - In a sub-group analysis of the effect of Opsumit on hospitalizations, there were 117 (46.8%), 104 (41.6%), and 90 (37.2%) patients in the placebo, Opsumit 3 mg and 10 mg groups, respectively, who were hospitalized for any cause at least once during double-blind treatment, and they experienced a total of 171, 159, and 135 all-cause hospitalizations, respectively. Compared with that of placebo, the risk of all-cause hospitalization with Opsumit 3 mg
was reduced by 18.9% (HR, 0.811; 95% CI, 0.623 to 1.057; p = 0.1208) and with Opsumit 10 mg by 32.3% (HR, 0.677; 95% CI, 0.514 to 0.891; p = 0.0051). Compared with placebo, the rate of PAH-related hospitalization was reduced by 44.5% in the Opsumit 3 mg group (p = 0.0004) and by 49.8% in the Opsumit 10 mg group (p < 0.0001). The mean number of annual hospital days for PAH-related hospitalizations was reduced by 53.3% in the Opsumit 3 mg arm (p = 0.0001) and by 52.3% in the Opsumit 10 mg arm (p = 0.0003). Due to the exploratory nature of this endpoint and small population, data from this study must be interpreted cautiously (Channick et al 2015).

Remodulin (treprostinil)

The safety and efficacy of Remodulin were evaluated in 2 identical 12-week, multicenter, randomized, placebo-controlled, double-blind trials in a total of 470 patients with NYHA Class II, III, and IV PAH. Remodulin was administered SC at an average dose of 9.3 ng/kg/min. The effect on the 6MWD was small and did not achieve statistical significance at 12 weeks. For the combined populations, the median change from baseline for patients on Remodulin was 10 m and the median change from baseline on placebo was 0 m from a baseline of approximately 345 m. Remodulin significantly improved the Borg dyspnea score during the 6-minute walk test. Remodulin also consistently improved indices of dyspnea, fatigue, and signs and symptoms of PH. However, these results were difficult to interpret in the context of incomplete blinding to treatment assignment resulting from infusion site symptoms.

Orenitram (treprostinil)

The efficacy and safety of Orenitram were evaluated in 3 multicenter, randomized, placebo-controlled, double-blind trials in 349 patients (FREEDOM-M), 350 patients (FREEDOM-C), and 310 patients (FREEDOM-C2).

- FREEDOM-M compared twice daily administration of Orenitram with placebo in patients newly diagnosed with PAH and not receiving any background PAH treatment. The dose titration was based on patient’s clinical response and tolerability. The primary endpoint was change in 6MWD over 12 weeks. The Orenitram group showed a significant improvement in 6MWD of 23 m (p = 0.0125). More than 50% of patients had an improvement of ≥ 20 m, and over 30% of patients had an improvement of > 50 m (Jing et al 2013). Orenitram demonstrated AEs typical of prostacyclin treatments (Waxman 2013).

- FREEDOM-C and FREEDOM-C2 failed to meet the primary endpoint of improved 6MWD (Tapson et al 2012, Tapson et al 2013).

- The multicenter, randomized, double-blind FREEDOM-EV trial compared 3 times daily Orenitram to placebo in 690 patients who had recently started background therapy with sildenafil, tadalafil, bosentan, ambrisentan, macitentan, or riociguat. The primary endpoint was time to first adjudicated clinical worsening event. Patients receiving Orenitram were less likely to experience a clinical worsening event (HR, 0.74; 95% CI, 0.56 to 0.97; p = 0.028) (White et al 2020).

Revatio (sildenafil)

The safety and efficacy of Revatio were evaluated in the SUPER-1 study, a 12-week, randomized, double-blind, placebo-controlled trial consisting of 278 patients with predominantly WHO FC II or III symptoms. Compared to placebo, Revatio significantly improved exercise capacity, as measured by the 6MWD, WHO FC symptoms and hemodynamics (Galiè et al 2005). In a 3-year extension study (SUPER-2), 46% of patients increased 6MWD relative to SUPER-1 baseline, 18% decreased 6MWD from baseline, 19% had died and 17% discontinued treatment or were lost to follow-up (Rubin et al 2011). The addition of Revatio to epoprostenol was evaluated in PACES, a 16-week, randomized, double-blind, placebo-controlled trial consisting of 267 patients receiving epoprostenol with predominantly WHO FC II or III symptoms. Revatio added to epoprostenol improved exercise capacity, hemodynamic measurements and time to clinical worsening more than epoprostenol plus placebo (Simonneau et al 2008).

Tracleer (bosentan)

Tracleer was originally FDA-approved in PAH patients with WHO FC III and IV symptoms based on the results from 2 randomized, double-blind, placebo-controlled trials in 32 (Study 351) and 213 (BREATHE-1) patients treated for 16 and 12 weeks, respectively. In both studies, significant increases in the 6MWD were observed in all Tracleer groups compared to placebo. Tracleer was also associated with a significant reduction in dyspnea during walk tests and a significant improvement in WHO FC symptoms (Channick et al 2001, Rubin et al 2002). The FDA-approved indication was subsequently expanded to include patients with WHO FC II symptoms based on the results of the EARLY study consisting of 168 patients. In this 26-week study, treatment with Tracleer resulted in an increase in the 6MWD of 11.2
m compared to a decrease of 7.9 m in the placebo group; however, the difference was not statistically significant. The study did show a significant delay in clinical worsening and a lower incidence of worsening FC symptoms in the Tracleer group compared to placebo (Galiè et al 2008[b], McLaughlin et al 2006).

- The results of an open-label extension phase of the EARLY trial suggested that the majority of patients exposed to long-term Tracleer therapy maintained or improved their FC. Approximately 20% of patients discontinued treatment because of AEs, which were most commonly PAH worsening (defined as death or initiation of IV or SC PCAs) and elevated liver enzymes. Due to lack of a control group, data from this study must be interpreted cautiously (Simonneau et al 2014).

- The COMPASS-2 trial (n = 334) was a prospective, double-blind, randomized controlled trial consisting of symptomatic PAH patients ranging from WHO FC II to IV who were taking stable Revatio doses (mean dose, 60 mg) for ≥ 3 months. Patients were randomized to Tracleer 125 mg twice daily plus Revatio or placebo plus Revatio for 16 weeks. There was no difference in the primary endpoint, time to the first morbidity/mortality event (defined as time to all-cause death, hospitalization for worsening PAH, initiation of IV prostanoïd, atrial septostomy, lung transplant, or worsening PAH). There were also no significant differences in the individual measures of the primary endpoint; however, observed benefits were seen in terms of the mean 6MWD test. A high drop-out rate was observed during the trial; therefore, study power was reduced (McLaughlin et al 2015).

**Tyvaso (treprostinil)**

- The safety and efficacy of Tyvaso were evaluated in TRIUMPH I, a 12-week, multicenter, randomized, placebo-controlled, double-blind trial in WHO Group I PAH (98% NYHA Class III) patients who were receiving either Tracleer or Revatio (n = 235) for at least 3 months prior to study initiation. Patients received either placebo or Tyvaso in 4 daily treatments with a target dose of 9 breaths (54 mcg) per session. The primary endpoint, 6MWD, was measured at peak exposure (10 to 60 minutes post dose) and 3 to 5 hours after Tracleer or 30 to 120 minutes after Revatio. Patients receiving Tyvaso had a placebo-corrected median change from baseline in peak 6MWD of 20 meters (m) at week 12 (p < 0.001). The 6MWD measured at trough significantly (measured 4 hours after dosing) improved by 14 m.

- In a long-term follow-up of patients who were treated with Tyvaso in the pivotal study and the open-label extension (n = 206), Kaplan-Meier estimates of survival at 1, 2, and 3 years were 97%, 91%, and 82%, respectively. Of note, these observations were uncontrolled and therefore cannot be compared to the control group to determine the long-term effect of Tyvaso on mortality.

**Uptravi (selexipag)**

- The safety and efficacy of Uptravi were evaluated in the GRIPHON study (n = 1,156), a randomized, double-blind, placebo-controlled trial consisting of patients with predominantly idiopathic PAH, and WHO FC II or III symptoms. The median duration of treatment varied from 1.2 to 1.4 years for placebo and Uptravi, respectively, and treatment end was defined as 7 days after the last day of treatment intake. Compared to placebo, Uptravi significantly reduced the composite endpoint signifying the time to progression of PAH, defined as all-cause death or a PAH complication (27% vs. 41.6%; HR, 0.6; 99% CI, 0.46 to 0.78; p < 0.001); however, there were no differences in mortality between groups. The reduction in PAH complications was primarily driven by a reduction in disease progression (17.2% vs. 6.6%) and PAH-related hospitalization (18.7% vs. 13.6%). The safety of Uptravi compared to other agents in class is not clear. The GRIPHON pre-specified sub-group analysis did not stratify AEs by background treatment, but the study allowed stable doses of PDE-5 inhibitors and/or an ERA which accounted for approximately 80% of patients within the placebo baseline group. Those AEs that occurred significantly more often with Uptravi treatment included headache, diarrhea, jaw pain, nausea, myalgia, vomiting, extremity pain, flushing (p < 0.001 for all AEs), anemia (p = 0.05), and hyperthyroidism (p = 0.004) (Sitbon et al 2015).

- Frost and colleagues demonstrated that transitioning patients from inhaled treprostinil to Uptravi was effective and safe (Frost et al 2018). Of 34 enrolled patients, 32 (94.1%) stopped inhaled treprostinil and were receiving Uptravi, with 28 patients (82.4%) meeting all criteria for sustained treatment transition. In general, patients remained clinically stable throughout therapy and reported improved outcomes.

**Veletri (epoprostenol)**

- Please refer to the clinical efficacy summary for Flolan above.

**Ventavis (iloprost)**

- Please refer to the clinical efficacy summary for Fiolan above.
The efficacy of Ventavis was evaluated in a 12-week, randomized, multicenter, double-blind, placebo-controlled trial consisting of 203 patients with NYHA Class III PAH (majority), Class IV PAH, or CTEPH. Patients received 2.5 or 5 mcg of Ventavis 6 to 9 times daily during waking hours. The difference in the primary composite endpoint (10% increase in 6MWD 30 minutes after dose, improvement by at least one NYHA class compared to baseline, and no death or deterioration of PH) was statistically significant (19% vs. 4% placebo, p = 0.0033). The results for the CTEPH patients were not included in the aforementioned results, since there was inadequate evidence of benefit in this patient population. The placebo-corrected difference in the 6MWD in Ventavis patients at 12 weeks was 40 m (p < 0.01).

The safety of Ventavis was evaluated in a prospective, 2 year, open-label study with 63 PAH patients. Patients received Ventavis 2 to 4 mcg 6 to 9 times daily. Thirty-six patients completed at least 630 days of therapy, 19 patients dropped out prematurely, and 8 patients died. AEs were mild to moderate, the most common of which were cough and flushing. Two-year survival was found to be 87% [95% CI, 76% to 98%] (Olschewski et al 2010).

Meta-analyses and systematic reviews

The results of a meta-analysis of 18 randomized controlled trials (n = 4,363) suggested that all oral PAH therapies confer a therapeutic benefit. More specifically, the findings showed:

- PDE-5 inhibitors were associated with a statically significant reduction in mortality (relative risk [RR], 0.22; 95% CI, 0.07 to 0.71; p = 0.011), while other drugs only showed a trend toward reducing mortality.
- Compared with placebo, ERAs, PDE-5 inhibitors, and riociguat significantly reduced clinical worsening, ameliorated WHO function class, and increased 6MWD. Oral prostanoids only showed a mild effect on 6MWD (19.88 m; 95% CI, 10.12 to 29.64, p = 0), and did not have any effect on reducing mortality and clinical worsening. Additionally, oral prostanoids significantly increased the incidence of treatment discontinuation due to AEs (RR, 3.41; 95% CI, 2.06 to 5.63; p = 0) (Zheng et al 2014[a]).
- A meta-analysis of 14 randomized controlled trials (n = 2,244) that evaluated the improvement in overall survival with use of oral, SC, IV, and inhaled PCAs, suggested the following:
  - Only IV PCAs showed a survival benefit (RR, 0.36; 95% CI, 0.16 to 0.79; p = 0.011), while oral (RR, 0.73; 95% CI, 0.32 to 1.66; p = 0.446), inhaled (RR, 0.28; 95% CI, 0.05 to 1.67; p = 0.162), and SC administration (RR, 0.91; 95% CI, 0.38 to 2.20; p = 0.837) did not show a benefit.
  - Overall mortality in the 14 studies was 3.30% (74 of 2,244 patients) with 2.52% (30 of 1,189 patients) mortality in the PCA-treated group and 4.17% (44 of 1,055 patients) mortality in the placebo group. The cumulative RR estimate of death showed a significant reduction of 44% (RR, 0.56; 95% CI, 0.35 to 0.88; p = 0.01), and no heterogeneity (I² = 0.0%; p = 0.84) was detected among studies (Zheng et al 2014[b]).
- A 2019 meta-analysis of 17 randomized controlled trials evaluated the efficacy of PCAs (15 studies), including the prostacyclin receptor agonist Uptravi (2 studies), and demonstrated the following:
  - WHO functional class was improved with prostanoids (OR, 2.39; 95% CI, 1.72 to 3.32), largely due to improvements after IV and inhaled therapy but not after oral therapy.
  - IV prostanoioid therapy improved 6MWD (19.5 m; 95% CI, 14.82 to 24.19).
  - Mortality was reduced with IV prostanooid administration (OR, 0.29; 95% CI, 0.12 to 0.69) but not after administration by other routes.
  - Compared to placebo, Uptravi improved 6MWD (12.62 m; 95% CI, 1.90 to 23.34) and clinical worsening (OR, 0.47; 95% CI, 0.37 to 0.60), but no difference in mortality was observed (risk difference, 0.02; 95% CI, 0.00 to 0.04) (Barnes et al 2019[b]).
- The results of a meta-analysis of 21 randomized controlled trials (n = 5,105) suggested that there was a reduction in the number of combined clinical worsening events (defined as all-cause mortality, lung or heart-lung transplant, hospitalization for PAH, and escalation of treatment) in patients with PAH with oral treatments, but showed less favorable effects on life expectancy in the short-term follow-up. Results demonstrated:
  - All classes reduced clinical worsening compared to placebo, including oral prostanoids (odds ratio [OR], 0.616; 95% CI, 0.419 to 0.906; p = 0.014), ERAs (OR, 0.504; 95% CI, 0.409 to 0.621; p < 0.001), PDE-5 inhibitors (OR, 0.468; 95% CI, 0.329 to 0.664; p < 0.001), and Adempas (OR, 0.277; 95% CI, 0.098 to 0.782; p = 0.015).
  - There were no significant reductions in mortality with any class versus placebo (Zhang et al 2015).
- A meta-analysis of 5 randomized controlled trials (n = 962) of < 16 weeks duration in adults and children treated with an sGC stimulator determined the following (all comparisons are vs. placebo):
sGC stimulators improve PAP in patients with PAH (who are treatment naïve or receiving a prostanoid or ERA) or those with recurrent or inoperable CTEPH.

- Pooled analysis showed a mean difference in 6MWD of 30.13 m (95% CI, 5.29 to 54.96; I² = 64%). On subgroup analysis, for PAH, there was no effect on 6MWD (11.91 m; 95% CI, -44.92 to 68.75; I² = 77%), and for CTEPH, sGC stimulators improved 6MWD by a mean difference of 45 m (95% CI, 23.87 to 66.13; I² = 0%).
- The secondary outcome of mortality showed no change on pooled analysis.
- Although pooled results demonstrated an increase (improvement) in WHO FC (OR, 1.53; 95% CI, 0.87 to 2.72; I² = 49%), the results did not reach statistical significance. Also, there was no effect on clinical worsening (OR, 0.45; 95% CI, 0.17 to 1.14; I² = 54%) or a reduction in MAP (−2.77 mmHg; 95% CI, −4.96 to −0.58; I² = 49%). The pooled analysis did not show any significant difference in serious AEs (OR, 1.12; 95% CI, 0.66 to 1.90; I² = 39%).
- sGC stimulators should not be taken by people also receiving PDE-5 inhibitors or nitrates due to the risks of hypotension, and there is currently no evidence supporting their use in pulmonary hypertension associated with left heart disease (Wardle et al. 2016).

- Several additional meta-analyses have been conducted evaluating ERAs, PDE-5 inhibitors, and PCAs. Notable observations in meta-analyses include the following:
  - Survival benefit was seen more with IV PCAs, especially in patients with more severe disease, compared with other routes such as oral and inhalation (Ryerson et al. 2010).
  - ERAs (Letairis and Tracleer) may have a somewhat lower effect on exercise tolerance in patients with connective tissue diseases, whereas PDE-5 inhibitors (Revatio and Adcirca) and the PCA epoprostenol showed consistent effects regardless of the presence or absence of connective tissue diseases (Kuwana et al. 2013).
  - Combination therapy appears to improve exercise capacity and reduce the risk of clinical worsening in PAH patients compared with monotherapy (Zhu et al. 2012).

- A network meta-analysis of 16 randomized controlled trials concluded that add-on therapy with Adcirca or Tyvaso improved 6MWD compared to ERAs alone, add-on therapy with Opsumit or Tracleer improved 6MWD compared to PDE-5 inhibitors alone, and add-on therapy with PDE-5 inhibitors improved 6MWD compared to epoprostenol alone. However, differences in all-cause mortality were not significant (Petrovic et al. 2020).

- Favorable effects on clinical events were not predicted by changes in the 6MWD (Savarese et al. 2012). In addition, pulmonary hemodynamics correlated with exercise capacity, but not with clinical events (Savarese et al. 2013).

- According to an Agency for Healthcare Research and Quality meta-analysis, prostacyclin analogues showed a statistically significant improvement in mortality. In addition, all drug classes improved 6MWD, but comparisons between agents were inconclusive. Combination therapy also improved 6MWD compared with monotherapy, but comparisons between specific regimens were inconclusive. Patients taking ERAs and PDE-5 inhibitors had a lower risk of hospitalization than those taking placebo, while the reduction in patients taking PCAs compared with placebo was similar, but not statistically significant (McCrory et al. 2013).

- A meta-analysis including 15 RCTs comparing combination and monotherapy for the treatment of PAH found that the absolute risk reduction of clinical worsening was relatively constant beyond a 6 to 12-month treatment duration, and cast doubt on the need for trials of longer duration for measuring treatment efficacy in this population (Lajoie et al. 2018).

- A Cochrane review of PDE-5 inhibitors for pulmonary hypertension concluded that these agents have clear beneficial effects in Group 1 PAH (Barnes et al. 2019[a]). For Group 2 PAH, there appears to be some benefit; however, it is unclear which type of left heart disease stands to benefit from therapy. Additionally, there is no clear benefit for PDE-5 inhibitors in PAH secondary to lung disease or CTEPH.

### CLINICAL GUIDELINES

- Several published clinical guidelines on PAH are available.
  - The Chest Guideline and Expert Panel Report 2019 update on pharmacologic therapy for PAH recommends initial combination therapy rather than monotherapy, which is a change from the 2014 guideline (Klinger et al. 2019).
    - **Initial therapy:** For patients in WHO FC II or III, combination therapy with Letairis and Adcirca is recommended to improve 6MWD. For patients unwilling or unable to take combination therapy, monotherapy with an ERA, PDE-5 inhibitor or sGC is recommended. WHO FC III patients with evidence of rapid progression or markers of poor prognosis, a parenteral PCA should be considered. For patients in WHO FC IV, a parenteral PCA is recommended; however, if patients are unable or unwilling to manage a parenteral product, an alternative is an inhaled PCA combined with an ERA and an oral PDE-5 inhibitor.
### Subsequent therapy:
For patients in WHO FC III who have evidence of progression or markers of poor prognosis despite treatment with one or two classes of oral agents, addition of an inhaled or parenteral prostanoid should be considered. In patients in WHO FC III or IV, if clinical status is unacceptable, a second (and if needed, a third) class of PAH therapy can be added.

- Due to limited evidence, the guideline does not provide recommendations for or against the use of Orenitram or Uptravi.

  - The European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of PH (Galiè et al 2015[b]) provide several options for both monotherapy and combination therapy of PAH.

  - **Monotherapy:** For patients in WHO FC II, recommendations include an ERA, a PDE-5 inhibitor, an sGC stimulator, or a prostacyclin receptor agonist. For patients in WHO FC III, the same medications may be used, and another option is a PCA. PCAs (eg, epoprostenol) are generally preferred for patients in WHO FC IV.

  - **Initial drug combination therapy:** Only the combination of Adcirca and Letairis has a category I recommendation for patients in WHO FC II and III; this combination also has a category IIb recommendation for patients in WHO FC IV. Other double- and triple-therapy combinations are also options, including other ERA and PDE-5 inhibitor combinations (WHO FC II, III, and IV) and some combinations of oral therapies with parenteral PCAs (WHO FC III and IV).

  - **Sequential drug combination therapy:** Several options are provided for sequential combination therapy. Oral combinations are commonly recommended for patients in WHO FC II and III, including Opsumit added to Revatio, Adempas added to Tracleer, and Uptravi added to an ERA and/or a PDE-5 inhibitor. Other oral combinations and combinations of oral therapies with inhaled or parenteral agents may also be used in patients in WHO FC II, III, and/or IV, but in most cases these recommendations are not as strong.

- A 2018 scientific statement on the evaluation and management of right-sided heart failure from the American Heart Association (AHA) summarizes data for the use of prostacyclin analogs, PDE-5 inhibitors, and endothelin receptor agonists in patients with PAH (Konstam et al 2018). However, specific recommendations concerning the use of these agents in the PAH population are not provided in this document.

  - Reputable society groups agree that evidence supporting pediatric treatment is lacking. The AHA and American Thoracic Society (ATS) published a guideline on pediatric PH. This guideline states that in pediatric patients with lower-risk PAH, oral therapy with either a PDE-5 inhibitor or an ERA is recommended, and in pediatric patients with higher-risk PAH, IV or SC PCAs should be initiated without delay (Abman et al 2015). An expert consensus statement from the European Pediatric Pulmonary Vascular Disease Network (endorsed by the Association for European Pediatric and Congenital Cardiology, the European Society for Pediatric Research, and the International Society of Heart and Lung Transplantation) recommends a PDE-5 inhibitor, ERA, or oral/inhaled prostacyclin agonist therapy for pediatric patients with low- or intermediate-risk PAH. Initial combination therapy with a PDE-5 inhibitor and an ERA may be considered for patients who are at intermediate risk. Higher-risk patients should be treated with intravenous epoprostenol or intravenous or subcutaneous treprostinil; early combination therapy with a PDE-5 inhibitor, an ERA, and a PCA may also be considered in these patients (Hansmann et al 2019).

---

### SAFETY SUMMARY

- **sGC Stimulator**
  - Adempas has a boxed warning due to embryo-fetal toxicity. It is contraindicated in pregnancy because it may cause fetal harm when administered to pregnant women.
  - Females can only receive Adempas through the Adempas REMS Program, a restricted distribution program that requires enrollment and certification of prescribers, patients, and pharmacies. The program also requires females of reproductive potential to comply with pregnancy testing and contraception requirements.
  - Adempas is contraindicated in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias.
  - Additional contraindications for Adempas include co-administration with nitrates or nitric oxide donors and PDE-inhibitors (specific and non-specific).
  - Warnings and precautions for Adempas include symptomatic hypotension, bleeding, and pulmonary edema in patients with veno-occlusive disease (if confirmed, treatment should be discontinued).
  - The most common AEs associated with Adempas include headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, and constipation.

---

Data as of May 15, 2020

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
• **ERAs**
  - The ERAs (Letairis, Opsumit, and Tracleer) have boxed warnings for embryo-fetal toxicity and/or risks of teratogenicity due to the potential for fetal harm when administered to women who are or may become pregnant.
  - The Ambrisentan and Opsumit REMS programs, respectively, are designed in the same manner as the Adempas REMS program described above.
  - The Bosentan REMS program requires healthcare professionals who prescribe or dispense this product to enroll and comply with requirements, which include monthly reviews of pregnancy tests in women of reproductive potential and liver enzymes and bilirubin in all patients. All patients must understand the risks and complete an enrollment form.
  - Letairis has an additional contraindication for idiopathic pulmonary fibrosis (IPF).
  - Tracleer has additional contraindications for use with cyclosporine A or with glyburide.
  - Tracleer has an additional boxed warning for risks of hepatotoxicity and birth defects. Throughout treatment and for 1 month after stopping Tracleer, females of reproductive potential must use 2 reliable methods of contraception unless the patient has had a tubal sterilization or had an intrauterine device (IUD) inserted.
  - Drug Reaction with Eosinophilia and Systematic Symptoms (DRESS), anaphylaxis, rash, and angioedema have been reported with Tracleer.
  - Pulmonary edema/fluid retention has been reported during postmarketing surveillance of Letairis and Tracleer. Fluid retention may occur within weeks after starting Letairis and is more common when Letairis is used in combination with Adcirca than with Letairis or Adcirca alone.
  - Use of Opsumit and Tracleer should be avoided in patients taking potent inhibitors or inducers of CYP3A.
  - Decreases in sperm count, decreased hemoglobin and hematocrit levels, and pulmonary edema (associated with pulmonary veno-occlusive disease [PVOD]) have been observed in patients taking ERAs.

• **PDE-5 Inhibitors**
  - All PDE-5 inhibitor products have a contraindication for use in patients on nitrates as well as a warning with concomitant alpha blocker use due to resulting hypotension. The patient should allow 48 hours to elapse between the last dose of Adcirca and taking nitrates. Additionally, Revatio and Adcirca are contraindicated for concomitant use with the sGC stimulator, Adempas.
  - In August 2012, the prescribing information for Revatio was updated with a warning stating that the use of Revatio in pediatric patients is not recommended due to increased mortality associated with higher doses and noted that lower doses are not effective in improving exercise capacity. The FDA clarified the warning related to pediatric use of Revatio in March 2014, stating it was not intended to suggest that Revatio never be used in children. The FDA acknowledged there may be situations in which the benefit-to-risk profile may be acceptable in individual children, for example, when other treatment options are limited, in which case Revatio can be used with close monitoring (FDA Drug Safety Communication, 2014).
  - Warnings and precautions for Adcirca and Revatio include prolonged erection (for more than 4 hours), hearing loss, and vision loss (in 1 or both eyes), all of which require immediate medical attention.
  - Co-administration of Revatio or Adcirca with potent CYP3A inhibitors is not recommended. Co-administration of Adcirca with potent CYP3A inducers is not recommended.
  - Blood pressure lowering effects are increased when Adcirca is taken with alcohol.
  - Revatio and Adcirca are generally well tolerated with headaches, myalgia, flushing, and dyspepsia being the most common AEs reported for both products.
  - Stevens-Johnson syndrome and exfoliative dermatitis have been reported with Adcirca, anaphylactic reaction, anaphylactic shock and anaphylactoid reaction have been reported with Revatio.
  - Vision loss, including permanent vision loss because of non-arteritic anterior ischemic optic neuropathy has been reported with the use of PDE-5 inhibitors.

• **Prostacyclin Receptor Agonist**
  - **Uptravi is contraindicated with strong CYP2C8 inhibitors.**
  - Uptravi has a warning/precaution to consider PVOD if acute pulmonary edema develops.
  - Uptravi is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) and has not been studied in dialysis patients (or with eGFR < 15 mL/min/1.73m²).
  - Concomitant administration of Uptravi is contraindicated with strong inhibitors of CYP2C8 (eg, gemfibrozil).
  - The most common AEs reported with Uptravi are headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing. These AEs are more frequent during the dose titration phase.

• **PCAs**
Orenitram is contraindicated for use in patients with severe hepatic impairment (Child-Pugh Class C).

Flolan and Veletri are contraindicated in patients with heart failure due to severe left ventricular dysfunction. Additionally, Veletri is contraindicated in patients with pulmonary edema, stating that the development of pulmonary edema during dose initiation may be associated with pulmonary veno-occlusive disease.

Orenitram and Tyvaso both carry a warning/precaution related to an increased risk of bleeding, particularly in patients receiving anticoagulants. Remodulin inhibits platelet aggregation and thereby can increase the risk of bleeding. Additional warnings and precautions for Tyvaso include symptomatic hypotension, possible Tyvaso dose changes when inhibitors or inducers of CYP2C8 are added or withdrawn, and a possible increase in exposure or a decrease in tolerability with hepatic or renal impairment. Orenitram should be avoided in patients with blind-end pouches (diverticulosis).

The safety of Tyvaso and Ventavis has not been established in patients with significant underlying lung disease (e.g., asthma, chronic obstructive pulmonary disease, acute pulmonary infections). Patients with acute pulmonary infections who are taking Tyvaso should be carefully monitored to detect any worsening of lung disease and loss of drug effect. Ventavis can induce bronchospasm.

Hypotension leading to syncope has been observed with Ventavis. It should not be administered in patients with a systolic blood pressure below 85 mmHg. Remodulin can cause symptomatic hypotension.

Flolan and Ventavis carry additional warnings and precautions regarding pulmonary edema. If signs of pulmonary edema occur, treatment should be stopped because this could be a sign of pulmonary venous hypertension or pulmonary veno-occlusive disease.

With Flolan, Orenitram, Remodulin, and Veletri, abrupt withdrawal (including interruptions in drug delivery) or sudden large reductions in the dose can worsen PAH symptoms (or cause rebound PH in patients taking Flolan).

Flolan carries additional warnings and precautions that include vasodilation reactions and an increased risk of bleeding.

Flolan, Remodulin, and Veletri are administered via an indwelling central venous catheter. This route of administration is associated with blood stream infections (BSI) and sepsis, which may be fatal. During long-term follow-up, sepsis was reported at a rate of 0.3 infections per patient per year in patients treated with Flolan. In an open-label study of IV Remodulin using an external infusion pump (n = 47), there were 7 catheter-related line infections during approximately 35 patient years, or about one BSI event per 5 years of use. A Centers for Disease Control and Prevention survey of 7 sites that used IV Remodulin for the treatment of PAH found approximately one BSI event per 3 years of use. In an open-label study of an implantable pump (n = 60), there were 2 BSIs related to the implant procedure during approximately 265 patient-years. Continuous SC infusion (undiluted) is the preferred mode of administration of Remodulin. Veletri was associated with chills/fever/sepsis/flu-like symptoms in 25% of patients in controlled trials for idiopathic or heritable PAH.

Ventavis solution should not be allowed to come into contact with skin or eyes, and ingestion should be avoided.

Remodulin and Tyvaso exposure may increase or decrease when administered with strong inhibitors or inducers of CYP2C8.

AEs reported with Tyvaso include cough, headache, throat irritation/pharyngolaryngeal pain, nausea, flushing, and syncope. AEs with Remodulin include infusion site pain, infusion site reaction, headache, diarrhea, nausea, rash, jaw pain, vasodilation, dizziness, edema, pruritus, and hypotension. The most common AEs reported with Orenitram include headache, diarrhea, nausea, and flushing.

AEs associated with Ventavis include vasodilation (flushing), increased cough, headache, trismus, insomnia, nausea, hypotension, vomiting, increased alkaline phosphatase, flu syndrome, back pain, tongue pain, palpitations, syncope, increased gamma-glutamyl transpeptidase, muscle cramps, hemoptysis, and pneumonia.

The most common AEs reported with Flolan and Veletri include dizziness, jaw pain, nausea, vomiting, headache, hypotension, flushing, and musculoskeletal pain.

### DOSING AND ADMINISTRATION

**Table 3. Dosing and Administration**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adcirca (tadalafil)</td>
<td>Tablet: 20 mg</td>
<td>Oral</td>
<td>Daily</td>
<td>Dividing the dose over the course of the day is not recommended.</td>
</tr>
</tbody>
</table>

Data as of May 15, 2020 LK-U/ME-U/AKS

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Available Formulations</th>
<th>Route</th>
<th>Usual Recommended Frequency</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adempas</td>
<td>Tablet: 0.5, 1, 1.5, 2, and 2.5 mg</td>
<td>Oral</td>
<td>Three times daily</td>
<td>Patients who smoke may tolerate higher doses. If they stop smoking, dose decreases may be required. Lower starting doses should be considered in patients unable to tolerate the hypotensive effects and patients receiving strong CYP and P-gp/BCRP inhibitors. Adempas may be crushed and mixed with water or soft foods immediately before administration. Discontinue at least 24 hours prior to administering a PDE-5 inhibitor. Pregnancy test required prior to treatment initiation, monthly during treatment, and one month after stopping treatment.</td>
</tr>
<tr>
<td>(riociguat)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flolan</td>
<td>Powder for injection: 0.5 and 1.5 mg</td>
<td>IV</td>
<td>Continuous infusion; Initiating infusion through a central venous catheter at 2 ng/kg/min; increase in increments of 1 to 2 ng/kg/min at intervals of at least 15 minutes based on clinical response. Abrupt withdrawal or sudden large reductions in infusion rates should be avoided. Continuous chronic infusion is administered through a central venous catheter. Temporary peripheral IV infusion may be used until central access is established.</td>
<td></td>
</tr>
<tr>
<td>(epoprostenol)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letairis</td>
<td>Tablet: 5 and 10 mg</td>
<td>Oral</td>
<td>Once daily (with or without tadalafil); titrate at 4-week intervals</td>
<td>Doses &gt; 10 mg once daily have not been studied. Tablets should not be split, crushed, or chewed. Pregnancy test required prior to treatment initiation, monthly during treatment, and one month after stopping treatment.</td>
</tr>
<tr>
<td>(ambrisentan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opsumit</td>
<td>Tablet: 10 mg</td>
<td>Oral</td>
<td>Once daily</td>
<td>Doses &gt; 10 mg once daily are not recommended. Pregnancy test required prior to treatment initiation, monthly during treatment, and one month after stopping treatment.</td>
</tr>
<tr>
<td>(macitentan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orenitram</td>
<td>Extended-release tablet: 0.125, 0.25, 1, 2.5, and 5 mg</td>
<td>Oral</td>
<td>Twice or 3 times daily; maximum dose is determined by</td>
<td>Should be taken with food. Tablets should be swallowed whole.</td>
</tr>
<tr>
<td>(treprostinil)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Available Formulations</td>
<td>Route</td>
<td>Usual Recommended Frequency</td>
<td>Comments</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------------------</td>
<td>-------</td>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Remodulin (treprostinil)</td>
<td>Multi-dose vials for injection: 1, 2.5, 5, 10 mg/mL</td>
<td>SC, IV</td>
<td>Continuous infusion; initial dose for patients new to therapy: 1.25 ng/kg/min; increase in increments of 1.25 to 2.5 ng/kg/min at weekly intervals, depending on clinical response</td>
<td>SC is preferred, although administration via a central IV line can be performed if SC administration is not tolerated. An implantable IV infusion pump has been approved for use with Remodulin (Implantable System for Remodulin or ISR). Refer to the pump manufacturer's manual for specific instructions for use. Use a lower starting dose in patients with mild or moderate hepatic impairment. Coadministration with CYP2C8 inhibitors (eg, gemfibrozil) and the presence of mild hepatic impairment require a lower starting dose. Avoid use in moderate hepatic impairment; contraindicated in severe hepatic impairment.</td>
</tr>
<tr>
<td>Revatio (sildenafil)</td>
<td>Tablet: 20 mg Powder for oral suspension: 10 mg/mL Solution for injection: 10 mg/12.5 mL</td>
<td>Oral, IV</td>
<td>Oral: 3 times daily approximately 4 to 6 hours apart Injection: IV bolus 3 times daily</td>
<td>Doses above 20 mg 3 times daily are not recommended. Revatio 10 mg injection dose is predicted to be the equivalent of a 20 mg oral dose. Revatio injection is for continued treatment of patients who are temporarily unable to take oral treatment. Oral suspension expires within 60 days of reconstitution.</td>
</tr>
<tr>
<td>Tracleer (bosentan)</td>
<td>Tablet: 62.5 and 125 mg Tablet for oral suspension: 32 mg</td>
<td>Oral</td>
<td>Twice daily (age and weight based dosing) Concurrent ritonavir: Once daily or every other day in patients who have been receiving ritonavir for ≥ 10 days; discontinue Tracleer at least 36 hours prior to initiation of ritonavir; resume Tracleer 10 days following ritonavir initiation</td>
<td>Tablets for oral suspension should be dispersed in a minimal amount of water immediately before administration. Pregnancy test required prior to treatment initiation, monthly during treatment, and one month after stopping treatment. Initiation should be avoided in patients with aminotransferases &gt; 3x ULN. Doses &gt; 125 mg twice daily do not have additional benefit sufficient to offset the increased risk of hepatotoxicity.</td>
</tr>
<tr>
<td>Tyvaso (treprostinil)</td>
<td>Inhalation solution (solution, refill, and starter solution): 0.6</td>
<td>Inhale</td>
<td>3 breaths per treatment session, 4 times a day (4 hours apart); titrate by an</td>
<td>Inhalation system consists of an ultrasonic, pulsed delivery device and its accessories.</td>
</tr>
<tr>
<td>Drug</td>
<td>Available Formulations</td>
<td>Route</td>
<td>Usual Recommended Frequency</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------</td>
<td>-------</td>
<td>------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Uptravi (selexipag) | Table: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 mcg  | Oral  | Twice daily; titrate dose weekly | Swallow tablets whole.  
Food may improve tolerability.  
*Use a once-daily starting dose in patients with moderate hepatic impairment, and reduce dosing to once daily in patients taking concomitant moderate CYP2C8 inhibitors.* |
|              | Titration pack: 200/800 mcg                                  |       |                              |                                                                          |
| Veletri (epoprostenol) | Powder for injection: 0.5 and 1.5 mg                        | IV    | Continuous infusion;  
Initiate infusion at 2 ng/kg/min; increase in increments of 2 ng/kg/min at intervals of at least 15 minutes based on clinical response  
If symptoms persist or recur after improving, increase in increments of 1 to 2 ng/kg/min at intervals of at least 15 minutes  
Abrupt withdrawal or sudden large reductions in infusion rates should be avoided.  
Continuous chronic infusion is administered through a central venous catheter. Temporary peripheral IV infusion may be used until central access is established. | |
|              |                                                            |       |                              |                                                                          |
| Ventavis (iloprost) | Inhalation solution: 10 and 20 mcg/mL                       | Inhale| Administered 6 to 9 times per day (no more than once every 2 hours); maximum: 9 times daily | Ventavis is intended to be inhaled using the I-neb Adaptive Aerosol Delivery (AAD) System.  
The 20 mcg/mL concentration is for patients who are maintained at the 5 mcg dose and who have repeatedly experienced extended treatment times, which could result in incomplete dosing.  
Vital signs should be monitored while initiating Ventavis. |

**Abbreviations:** CYP = cytochrome P450; IV = intravenous; P-gp/BCRP = P-glycoprotein/breast cancer resistance protein; SC = subcutaneous

**CONCLUSION**
- PAH is a life-threatening disorder that is associated with a poor prognosis.
- There are 5 classes of drugs that are used in the management of PAH, including ERAs, PDE-5 inhibitors, PCAs, a prostacyclin receptor agonist, and an sGC stimulator.
- All of the PAH agents have shown improved pulmonary hemodynamics and exercise capacity in PAH patients as compared to placebo. Meta-analyses have suggested statistically significant reduction in mortality with PDE-5 inhibitors and IV prostanooids *(Zheng et al 2014[a], Zheng et al 2014[b], Barnes et al 2019[b]).*
Most trials for PAH have been relatively short-term trials (12 to 18 weeks) that evaluated changes in exercise capacity using the 6-minute walk distance (6MWD) as a primary endpoint. However, recently there has been a preference toward longer, event-driven trials that evaluate composite clinical worsening events (LeVarge et al 2015). Published event-driven trials include SERAPHIN, GRIPHON, AMBITION, and COMPASS-2 (Galiè et al 2015[a], McLaughlin et al 2015, Pulido et al 2013, Sitbon et al 2015).

Clinical trials have demonstrated the safety and efficacy of the individual PAH agents, and some data are available on the use of combination therapy. Two trials evaluating combination therapy include the AMBITION and COMPASS-2 trials. The AMBITION trial demonstrated that combination treatment with Letairis and Adcirca resulted in reduced disease progression and hospitalization in mainly FC II and III PAH patients compared to monotherapy (Galiè et al 2015[a]). Results of this study are the primary driver of the change in the CHEST guidelines that recommend initial combination treatment with Letairis and Adcirca (Klinger et al 2019). However, the COMPASS-2 trial demonstrated no difference between Tracleer plus Revatio versus Revatio monotherapy for most endpoints with the exception of the mean 6MWD test (McLaughlin et al 2015).

Adempas is the first and only drug to be FDA-approved in the treatment of CTEPH. Pulmonary endarterectomy can be curative for CTEPH, but it is technically demanding which may limit access to its use as a treatment. Adempas is dosed 3 times daily, which is more frequent than several other oral treatments for PAH.

The ERAs (Letairis, Opsumit, and Tracleer) competitively bind to ET receptors with different affinities. Letairis and Opsumit are highly selective for the ETA receptor, while Tracleer is slightly selective for the ETA receptor over the ETB receptor. In addition, Opsumit has a pharmacologically active metabolite and is considered “tissue-targeting” because it displays high affinity and sustained occupancy at the ET receptors in human pulmonary arterial smooth muscles. However, the clinical significance of receptor affinities of the ERAs has not been established.

The PDE-5 inhibitors (Adcirca and Revatio) are generally well tolerated; the most common side effects include headache, myalgia, flushing, dizziness, and gastrointestinal upset. Both products are contraindicated for use in patients on nitrates and have warnings about their use in patients on alpha-adrenergic inhibitors. Use of Adcirca with potent CYP3A inhibitors or inducers may significantly alter serum levels of Adcirca and is not recommended. Use of Adcirca in patients who are using an sGC stimulator may potentiate the hypotensive effects of sGC stimulators and is not recommended. Use of Revatio with potent CYP3A inhibitors is not recommended as they may significantly alter serum levels of Revatio.

In addition to the oral tablet formulation, Revatio is available in an oral suspension formulation and an intravenous formulation.

Adcirca is taken once a day compared to 3 times a day with Revatio.

Orenitram is the first oral PCA approved by the FDA. The PCAs are frequently reserved for more severe forms of PAH. As the first oral option in this subclass for treatment of PAH, Orenitram may offer a more convenient alternative dosage form leading to earlier PCA initiation in treatment. Orenitram is dosed twice daily and requires dosage titration every 3 to 4 days.

Uptravi is a first-in-class prostacyclin receptor agonist, which works within the same pathway as Orenitram. Based on results from the GRIPHON trial, Uptravi has reduced disease progression and hospitalization. Uptravi has also demonstrated efficacy when combined with a PDE-5 inhibitor and/or an ERA. The safety of Uptravi compared to other oral agents in the class is not clear. The GRIPHON pre-specified sub-group analysis did not stratify AEs by background treatment, but the study allowed stable doses of PDE-5 inhibitors and/or an ERA throughout the trial. Background treatment was used by approximately 80% of patients within the placebo baseline group. Those AEs reported significantly more often with Uptravi treatment include headache, diarrhea, jaw pain, nausea, myalgia, vomiting, extremity pain, flushing, anemia, and hyperthyroidism (Sitbon et al 2015). Based on indirect trial evidence, the proportion of patients discontinuing Uptravi vs. placebo (14% vs. 7%) due to AEs in the GRIPHON trial was higher than those within the Orenitram labeling vs. placebo (4% vs. 3%) (Orenitram prescribing information 2014, Sitbon et al 2015). Overall, it is not clear how the Uptravi safety profile compares to other agents in class due to different study populations. Head-to-head trials are needed to confirm safety risks and differences.

The 2019 update to the 2014 CHEST Guideline and Expert Panel Report recommends initial combination therapy with Letairis plus Adcirca for treatment-naive symptomatic patients with WHO class II and III PAH. Alternatives include monotherapy with PDE-5 inhibitors, ERAs, and the sGC stimulator. Intravenous PCAs are recommended as initial or add-on treatment for patients with rapid progression and/or poor prognosis or for patients with WHO class IV PAH. Inhaled PCA is recommended as an add-on therapy for patients who remain symptomatic despite oral treatment. The update does not provide recommendations for or against the use of Orenitram or Uptravi (Klinger et al 2019).
The 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guideline stratifies PAH treatment by low-, intermediate-, or high-risk patients. In adult patients with low or intermediate risk (FC II to III), initial monotherapy or initial oral combination therapy is recommended. Based on the AMBITION trial, guidelines state that initial combination treatment with Letairis plus Adcirca has proven to be superior to initial monotherapy with either drug in delaying clinical failure. In adult patients with high risk (FC IV), initial combination therapy including IV PCAs is recommended, with epoprostenol IV considered first-line due to the mortality benefits in trials (Galiè et al 2015[b]).

The 2015 American Heart Association and American Thoracic Society guidelines recommend oral therapy with either a PDE-5 inhibitor or an ERA in lower-risk PAH pediatric patients. In pediatric patients with higher-risk PAH, IV and SC PCAs should be initiated immediately with a goal to transition patients to oral or inhaled therapy after the patient is asymptomatic and stable (Abman et al 2015). The 2015 ESC/ERS guidelines recommend that pediatric treatment follows adult guidelines, taking risks into account (Galiè et al 2015[b]). A 2019 expert consensus statement from the European Pediatric Pulmonary Vascular Disease Network (endorsed by the Association for European Pediatric and Congenital Cardiology, the European Society for Pediatric Research, and the International Society of Heart and Lung Transplantation) recommends a PDE-5 inhibitor, ERA, or oral/inhaled prostacyclin agonist therapy for pediatric patients with low- or intermediate-risk PAH. Initial combination therapy with a PDE-5 inhibitor and an ERA may be considered for patients who are at intermediate risk. Higher-risk patients should be treated with intravenous epoprostenol or intravenous or subcutaneous treprostinil; early combination therapy with a PDE-5 inhibitor, an ERA, and a prostacyclin agonist may also be considered in these patients (Hansmann et al 2019).

A 2018 scientific statement on the evaluation and management of right-sided heart failure from the AHA summarizes data for the use of PCAs, PDE-5 inhibitors, and ERAs in patients with PAH (Konstam et al 2018). However, specific recommendations concerning the use of these agents in the PAH population are not provided in the document.

REFERENCES


Publication Date: June 8, 2020